# A Clinical Study of TQH2929 Injection in Treatment With Generalized Pustular Psoriasis (GPP)

> **NCT06433531** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.** · enrollment: 9 (actual)

## Conditions studied

- Generalized Pustular Psoriasis

## Interventions

- **DRUG:** TQH2929 Injection

## Key facts

- **NCT ID:** NCT06433531
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-06-19
- **Primary completion:** 2025-07-08
- **Final completion:** 2025-12
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2025-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06433531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06433531, "A Clinical Study of TQH2929 Injection in Treatment With Generalized Pustular Psoriasis (GPP)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06433531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*